An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Pimavanserin (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Acadia Pharmaceuticals
- 23 Sep 2019 According to an ACADIA Pharmaceuticals media release, Primary endpoint (Change from Baseline to Week 8 in the Hamilton Depression Scale -17 items (HAMD-17) total score) has been met.
- 23 Sep 2019 Results presented in an ACADIA Pharmaceuticals Media Release.
- 23 Sep 2019 According to an ACADIA Pharmaceuticals media release, results were presented at he 2019 International Congress of Parkinsons Disease and Movement Disorders (MDS) in Nice, France.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History